SAB Biotherapeutics Inc SABS
News
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB BIO to Participate in Upcoming Investor Conferences
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
